GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transgene SA (LTS:0OCQ) » Definitions » Net Intangibles Purchase And Sale

Transgene (LTS:0OCQ) Net Intangibles Purchase And Sale : €-0.06 Mil (TTM As of Jun. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Transgene Net Intangibles Purchase And Sale?

Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Transgene's net Intangibles purchase and sale for the six months ended in Jun. 2024 was €-0.01 Mil. Its net Intangibles purchase and sale for the trailing twelve months (TTM) ended in Jun. 2024 was €-0.06 Mil.

Transgene Net Intangibles Purchase And Sale Historical Data

The historical data trend for Transgene's Net Intangibles Purchase And Sale can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Transgene Net Intangibles Purchase And Sale Chart

Transgene Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Intangibles Purchase And Sale
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.04 -0.04 -0.02 -0.04 -0.08

Transgene Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Net Intangibles Purchase And Sale Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.03 -0.03 -0.05 -0.01

Transgene Net Intangibles Purchase And Sale Calculation

Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Net Intangibles Purchase And Sale for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.06 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Transgene Net Intangibles Purchase And Sale Related Terms

Thank you for viewing the detailed overview of Transgene's Net Intangibles Purchase And Sale provided by GuruFocus.com. Please click on the following links to see related term pages.

Transgene Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transgene SA (LTS:0OCQ) » Definitions » Net Intangibles Purchase And Sale
Comparable Companies
XPAR:MAAT XPAR:IPH XPAR:ADOC XPAR:IVA XPAR:DBV XPAR:ABNX XPAR:NANO XPAR:AELIS XPAR:SIGHT XPAR:ALCLS VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
TNG:France TGNA:Germany
Address
400 Boulevard Gonthier d’Andernach, Parc d’Innovation, Illkirch-Graffenstaden, FRA, 67400
Website
https://www.transgene.fr
Transgene SA is a biotechnology company. The Company conducts its business exclusively in the clinical research and development of therapeutic vaccines and immunotherapeutic products. The company's clinical-stage programs are TG4010 for non-small cell lung cancer and Pexa-vec for liver cancer. Its product pipeline includes TG4001, TG1050, TG6002 etc. It is engaged in clinical research and development of therapeutic vaccines and immunotherapeutic products. The majority of its operations is located in France.

Transgene Headlines

No Headlines